Patients with end-stage liver disease (ESLD) often have a high symptom burden. Historically, palliative care (PC) services have been underused in this population. We investigated the use of PC services in patients with ESLD hospitalized across the United States. We used the Nationwide Inpatient Sample to conduct a retrospective nationwide cohort analysis. All patients >18 years of age admitted with ESLD, defined as those with at least two liver decompensation events, were included in the analysis. A multivariate logistic regression model predicting referral to PC was created. We analyzed 55,208,382 hospitalizations from the 2006-2012 Nationwide Inpatient Sample, with 39,349 (0.07%) patients meeting study inclusion. PC consultation was performed in 1,789 (4.5%) ESLD patients. The rate of PC referral in ESLD increased from 0.97% in 2006 to 7.1% in 2012 (P < 0.01). In multivariate analysis, factors associated with lower referral to PC were Hispanic race (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.66-0.89; P < 0.01) and insurance coverage (OR, 0.74; 95% CI, 0.65-0.84; P < 0.01). Factors associated with increased referral to PC were age (per 5-year increase, OR, 1.05; 95% CI, 1.03-1.08; P < 0.01), do-not-resuscitate status (OR, 16.24; 95% CI,; P < 0.01), treatment in a teaching hospital (OR, 1.25; 95% CI, 1.12-1.39; P < 0.01), presence of hepatocellular carcinoma (OR, 2.00; 95% CI, 1.71-2.33; P < 0.01), and presence of metastatic cancer (OR, 2.39; 95% CI, 1.80-3.18; P < 0.01). PC referral was most common in west coast hospitals (OR, 1.81; 95% CI, 1.53-2.14; P < 0.01) as well as large-sized hospitals (OR, 1.49; 95% CI, 1.22-1.82; P < 0.01). Conclusion: From 2006 to 2012 the use of PC in ESLD patients increased substantially; socioeconomic, geographical, and ethnic barriers to accessing PC were observed. (HEPATOLOGY 2017; 66:1585-1591.
nd-stage liver disease (ESLD) is an illness that can develop after the progression of chronic liver disease to advanced liver fibrosis/cirrhosis. In the United States an estimated 5.5 million people (2% of the population) are affected, resulting in ESLD being one of the top 12 causes of death. (1) (2) (3) Patients with ESLD can develop hepatic decompensation with events such as ascites, hepatic encephalopathy, hepatorenal syndrome, variceal bleeding, spontaneous bacterial peritonitis, and hepatocellular carcinoma (HCC). These decompensating events can occur in 5%-7% of individuals with cirrhosis annually, with a median transplant-free survival of 2 years. (4) The only existing cure for ESLD is liver transplantation, which is an option for a limited number patients given strict inclusion and exclusion criteria as well as a shortage of organs available for donation. (5) Patients with ESLD often have a significant symptom burden, including fatigue, abdominal pain, pruritus, confusion, and dyspnea from tense ascites. Quality of life can be negatively impacted by such physical symptoms, as well as the psychological complications of the illness for the patient and family. There is increasing awareness of the benefit of palliative care (PC) services for these patients in terms of symptom management and palliation. (5) (6) (7) (8) Unfortunately, data are limited regarding access to PC in patients with ESLD. Poonja et al. demonstrated that a lack of PC support network/service negatively impacted upon quality of life in a cohort of nontransplant candidates with ESLD; however, this was a single-center retrospective study with a small patient cohort. (9) Kathpalia et al., in another retrospective single-center study, demonstrated that only 17% of patients who died while awaiting a transplant received a PC consultation. (10) Thus, due to the limited literature on PC access for ESLD patients, we used the Nationwide Inpatient Sample (NIS) to investigate the management of these patients on a national multicenter scale. The primary objective of this study was to examine the use of PC in patients with ESLD admitted to hospitals across the United States. Secondary objectives included identifying barriers to PC access in order to develop strategies to improve the quality of care among ESLD patients.
Patients and Methods
We report our findings in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology statement. (11) The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of good clinical practice.
STUDY POPULATION
The 2006-2012 NIS was used for the analysis. The NIS is a federal all-payer database produced by the Agency for Healthcare Research and Quality that captures approximately 20% of all inpatient hospitalizations from 46 states and is capable of estimating the delivery of approximately 97% of all inpatient care delivered in the United States. (12) Thus, use of the NIS allows for analysis of patients across all sizes and types of hospitals, producing a robust characterization of patients.
We included all patients 18 years of age with a diagnosis of ESLD. We followed the validated algorithm 3 of Goldberg et al. for isolating patients with ELSD from administrative data. (13) We only included patients with an International Classification of Diseases, ninth edition (ICD9) code for chronic liver disease, as well as an ICD9 code for cirrhosis. Only patients who had two or more ICD9 codes for hepatic decompensation events were included in our cohort. The positive predictive value for identifying ESLD using this algorithm was 89.3%. (13) A full list of included ICD9 codes used in the selection process is displayed in the Supporting Information. Patients who underwent liver transplantation were excluded from the analysis (505.1, 505.9). A patient selection flow diagram is displayed in Fig. 1 .
The main cohort of patients was then segregated into patients who received a PC referral (ICD9 code V667) and those who did not. The reliance on ICD9 code V667 for characterizing a PC encounter has been validated to have a sensitivity of 81% and a specificity of 97% in patients with strokes. (14) Approximately 5% of hospitals included in the NIS samples during the entire study period did not have any referrals to PC regardless of diagnosis. The authors decided to include patients treated in these hospitals in the analysis in order to better characterize the delivery of PC to the ESLD population across the United States. While the inclusion of these hospitals in the analysis may bias toward lower rates of PC referral, in an effort to examine the true national access to PC for ESLD patients it was felt to be appropriate to include these smaller
hospitals which may not be equipped with inpatient PC referral teams.
We obtained the following patient demographics from the database: age, gender, race (white, black, hispanic, other), length of stay, in-hospital mortality, insurance coverage (yes versus no), and socioeconomic status (zip code income quartiles). The presence of metastatic and nonmetastatic cancer was based on the Elixhauser comorbidities for each category. The presence of HCC (155.0) was removed from the Elixhauser nonmetastatic cancer category and treated as a separate variable. The do-not-resuscitate (DNR) status (V4986) was also identified for each patient. Hospital characteristics gathered included bed size (small, medium, large, as defined by the Agency for Healthcare Research and Quality (12) ), US region (Northeast, Midwest, South, West), and university (teaching) hospital status (yes versus no).
CANCER COHORT SELECTION
In order to compare the rate of change of PC access to a population known to use PC, we created a cohort of patients with metastatic cancer during the same time period. We included patients 18 years of age with a diagnosis of metastatic cancer (ICD9 codes 196.x, 197.x, 198.x, and 199.x) in the cohort. PC consultation was again coded with ICD9 code V667.
STATISTICAL ANALYSIS
A multivariate logistic regression model for the use of PC referral was created. Variables included in the model were age, gender, insurance coverage, socioeconomic status, race, DNR status, metastatic cancer, nonmetastatic cancer, HCC, hospital size, hospital location, and hospital region. Percentages displayed in tables and figures represent national estimates. Independent t tests were used for continuous variables, while chi-squared testing was used for ordinal and nominal data. Data are presented with 95% confidence intervals where appropriate; P < 0.05 was considered statistically significant. Linear regression analysis was used for trend analysis of PC usage by year. All analyses were performed in SAS, version 9.4 (Cary, NC), using complex survey weights and procedures for appropriate national projections. patients. The rate of PC referral in ESLD increased from 0.97% in 2006 to 7.1% in 2012 (P < 0.01). Similarly, the rate of PC referral in cancer patients increased from 2.9% in 2006 to 11.9% in 2012 (P < 0.01; Fig. 1 ). The results of univariate analysis between those referred to PC and those who were not referred are displayed in Table 1 . The results of multivariate logistic regression modeling referral to PC are displayed in Table 2 . Factors associated with lower referral to PC were Hispanic race (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.66-0.89; P < 0.01) and insurance coverage (OR, 0.74; 95% CI, 0.65-0.84; P < 0.01). Factors associated with increased referral to PC were age (per 5-year increase, OR, 1.05; 95% CI, 1.03-1.08; P < 0.01), DNR status (OR, 16.24; 95% CI, 14.20-18.56; P < 0.01), treatment in a teaching hospital (OR, 1.25; 95% CI, 1.12-1.39; P < 0.01), presence of HCC (OR, 2.00; 95% CI, 1.71-2.33; P < 0.01), and presence of metastatic cancer (OR, 2.39; 95% CI, 1.80-3.18; P < 0.01).
The region of the country was also significantly associated with access to PC, with the Northeast serving as the reference; PC was more common in all other regions of the country: Midwest (OR, 1.31; 95% CI, 1.09-1.58; P < 0.01), South (OR, 1.24; 95% CI, 1.05-1.47; P 5 0.01), and West (OR, 1.81; 95% CI, 1.53-2.14; P < 0.01). Hospital size also influenced referral rates for PC, with large-sized (OR, 1.49; 95% CI, 1.22-1.82; P < 0.01) and medium-sized (OR, 1.36; 95% CI, 1.09-1.70; P < 0.01) hospitals referring patients more frequently than small hospitals. Higher rates of PC referral were also seen in the second median zip code income quartile compared to the lowest quartile (OR, 1.18; 95% CI, 1.04-1.35; P 5 0.01). There was a trend toward higher rates of referral in the third (OR, 1.09; 95% CI, 0.95-1.26; P 5 0.21) and fourth (OR, 1.08; 95% CI, 0.93-1.26; P 5 0.34) zip code income quartiles; however, these did not meet statistical significance.
Discussion
In this large, nationally representative analysis of patients with ESLD only a small minority of patients received a PC consultation. However, during the study period there was a dramatic increase in referral rates. Several socioeconomic, geographical, and ethnic barriers associated with differential rates of PC referral were identified. The current analysis is a nationwide examination of inpatient PC access for the ESLD patient population. The increased rate of referral to PC observed in our study can be explained by several factors. First, the role and awareness of PC in the management of patients with significant symptom burdens have increased over the past few years. While there has been a traditionally accepted role for PC in oncology patients, the benefits of PC in noncancer patients have been increasingly recognized. (15) (16) (17) (18) Moreover, increased referral to PC in larger teaching hospitals likely reflects the increased availability of specialized PC services and units in these hospitals as formal PC units and consultation teams have become commonplace in hospitals across the United States. (19) (20) (21) Our results build on the work previously published in the area of PC access for ELSD patients. Kathpalia et al. reported a 17% referral rate to PC for patients who were removed from an active transplantation list or died before transplant. (10) Similar to our results, they found an increased referral to PC for Caucasian patients compared to minority patients. While the absolute number of a 17% referral rate reported by Kathpalia et al. is higher than the rates found in our study, the study populations are different. Their analysis focused solely on patients who were enrolled in a liver transplantation program at a quaternary care referral center in San Francisco. Results of a singlecenter study should always be interpreted with a degree of caution, with the strength of our study reflecting multiple centers across the United States.
Our finding of differential access to PC services in low-socioeconomic status and Hispanic patients is not surprising as it is known that low-socioeconomic status and ethnic minorities have less access to health care services. (22) (23) (24) Hospice care and PC services have also been demonstrated to be less accessible to minorities and lower-income patients for numerous noncancer as well as cancer diagnoses. (17, (25) (26) (27) The results of this analysis support the existence of inequalities across subsets of the population and the need to address these disparities.
The association between insurance coverage and referral to PC services, with patients who have insurance coverage less likely to be referred, is interesting and needs to be validated. One question our results raise is if PC referral limits tests and treatments subconsciously and if this presents a conflict of interest with providers and hospitals in a fee-for-service payment system. If so, then a switch to bundle payment may improve referral to PC services.
The increased use of PC referral in ESLD patients with metastatic cancer as well as DNR status is to be expected but does warrant further investigation. In numerous other noncancer diagnoses, disparities in PC access have been demonstrated. (28) (29) (30) It is possible that patients with ESLD who have an additional cancer diagnosis may obtain PC due to their malignancy diagnoses rather than due to the diagnosis of liver disease. This may be due to the increased prevalence and awareness of the benefits of PC among oncology providers and services.
The strengths of the analysis include the large sample size and generalizability by examining patients across the entire United States. By including data from hospitals of all sizes and types, located across the United States, we were able to investigate the delivery of PC in diverse settings. The ability to study care delivery over a 7-year period also adds strength to our study by allowing for examination of temporal trends. However, the results of the analysis must be interpreted in the context of the study design. Use of retrospective discharge database information is inherently susceptible to coding errors and missing data. We were also unable to capture outpatient PC referrals, an important source of referral for the service. While referral to PC programs is common in oncology clinics, the rate of referral to these services from hepatology/gastroenterology clinics is unknown and worth further study on a large-scale basis. Lastly, we included patients with any two decompensating events which may be medically managed; however, our data set had no clinical information of types of treatments for the patients and how many were symptomatically stable and not requiring referral to PC. This would be impossible to estimate from such a data set; however, by excluding patients who were transplanted, we assume that patients suitable for liver transplant assessment were indeed transplanted-and if not, would have likely either been too well or unsuitable for PC referral. Also, by taking two or more decompensating events we attempted to identify a sick cohort of patients, as reported by D'Amico et al., (4) who may traditionally benefit from a PC referral if symptoms indicated or were deemed appropriate by the assessing physician. It should be stressed, in the authors' opinion, that PC referrals should be considered for patients dying with ESLD but also for the management of symptoms in patients with ESLD.
The increased use of PC in ESLD patients observed in the analysis is encouraging as these patients often have high symptom burden and interact with health care services frequently. However, the identified disparities of socioeconomic status, race, and hospital location and type should be addressed in designing PC services targeting the ESLD patient population as end-of-life issues are often not addressed until too late, if at all. (5, 9, 31) We hope our findings will serve as a platform for ongoing discussions around the benefit ESLD patients can derive from interactions with PC providers not only in the United States but also in other countries around the globe.
In conclusion, the use of PC consultation for patients with ESLD in the United States increased from 0.97% in 2006 to 7.1% in 2012. Higher socioeconomic status, DNR status, concurrent cancer diagnoses, and treatment in large teaching hospitals were associated with increased rates of referral. Hispanic race and health insurance coverage were associated with lower rates of referral.
